瑞齐替尼 I期临床：

1. A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of BPI-7711 in Patients with EGFR/T790M Mutation Advanced or Recurrent NSCLC 

发表于：

2. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

发表于：

瑞齐替尼 IIa期临床（一线）：

1. A phase IIa study to evaluate safety and efficacy of Rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation

2. Results of the phase IIa study to evaluate the efcacy and safety of rezivertinib (BPI-7711) for the frst-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

发表于：

瑞齐替尼 IIb期注册临床（二线）：

1. Efficacy and safety of Rezivertinib (BPl-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NsCLC: a phase Ilb, multicenter, single-arm, open-label study

发表于：

2. Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NSCLC: a phase IIb study

发表于：

3. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

发表于：

瑞齐替尼 III期注册临床（一线）：

1. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

发表于：